Skip to content
Annika Bansal – Lifestyle
Author:
Phathom Pharmaceuticals
Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026
October 12, 2026
Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting
October 8, 2026
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
September 29, 2026
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
September 1, 2026
Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
July 30, 2026
Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026
July 20, 2026
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
June 23, 2026
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
May 22, 2026
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
May 20, 2026
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
May 1, 2026
1
2
Next Page
→